Saturday, 10 July 2021, 12:51 pm
New Zealand most experienced vaccine researcher COVID-19
Vaccine Corporation (CVC) has signed a collaboration
agreement with not-for-profit Vaccine Formulation Institute
(VFI) in Switzerland.
CVC began its vaccine production
efforts in 2020 and is continuing to make progress with its
T cell COVID-19 vaccine. CVC’s vaccine is designed to
induce immunity to both current and yet unknown variants of
the SARS-CoV-2 virus, and will act as an enhancer to
existing vaccines currently available on the
market.
“It is particularly exciting to work with
VFI. We are now working with individuals that are global
experts in the use, application and formulation of vaccine
Tuesday, 23 February 2021, 1:10 pm
AUCKLAND: COVID-19 Vaccine Corporation (CVC) has joined
forces with the University of Queensland in its vaccine
production efforts.
After halting development of its
spike protein based candidate in December, CVC continues to
progress development of its proprietary T-cell
vaccine.
Its T-cell vaccine is designed to work with
other existing vaccines in order to improve efficacy,
lengthen immunity time and to protect against all new
variants for the SARS-Cov-2 virus, including those from
Britain and South Africa.
CVC’s efforts and new
partnership are particularly timely in the wake of South
African government’s attempt to recall a million doses of